Search results for: Multi-Indication Medicines
Filter search results
The commercial case for investing in ALS
13 November 2025
…require intensive, multidisciplinary care, with yearly per-patient healthcare costs ranging from $23,039 in Canada to $76,823 in the US. When extrapolated to national populations, these costs represent a significant strain…
Spotlight on OHE: Innovation, Regulation and Antibiotics
30 September 2014
…reference for pricing in other markets. How NICE expresses the value of medicines can be viewed as the NHS’s way of regulating innovation in prescription medicines. NICE bases its decisions…
Spotlight on OHE: Adaptive Pathways, Economic Evaluation, Stated Preferences and Life-cycle Price Modelling
5 November 2014
Medicines Adaptive Pathways: A Practical Strategy to Improve Patient Access to Medicines? In September 2014 the Centre for Innovation in Regulatory Science held a workshop with invited regulators, health…
H.R. 3 is the Wrong Policy for the Wrong Problem
10 September 2021
…the latest innovative medicines and technologies. Nearly 90% of all newly launched medicines are available in the US while only about half are available in other countries such as Canada…
Innovation in Medicines: Can We Value Progress?
1 August 2010
Summarised in this publication are the main points and conclusions from a discussion facilitated by OHE that focused on innovation in the pharmaceutical industry. Participants included representatives of the pharmaceutical…
European Medicines Pricing and Reimbursement: Now and the Future
1 January 2007
Available from Radcliffe publishing: https://www.radcliffe-oxford.com/books/bookdetail.aspx?ISBN=184619184X Published in association with the Office of Health Economics this book is a vital, non-technical guide illuminating recent developments within the five major European pharmaceutical…
Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
1 December 2021
…published the results of a research study describing how OBP could help accelerate patient access to some new medicines, ensure close monitoring of real-world patient benefits, promote value for money…
Around The World in HTAs: Spain – Are We There Yet?
15 March 2023
…(CISNS), which makes the final decisions that are then formally adopted and implemented by the MoH. Assessment of medicines After the European Medicines Agency marketing authorisation or approval, a government…
Drug shortages are on the rise – but what is their impact?
16 September 2024
…AAM, 2022. Report: 2022 U.S. Generic and Biosimilar Medicines Savings Report | Association for Accessible Medicines. [online] Available at: https://accessiblemeds.org/resources/reports/2022-savings-report [Accessed 10 Sep. 2024]. ASPE, 2023. ASPE Report to Congress: Impact of…